An observational study in Venous Thrombosis, sponsored by Bayer. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-18.
Sponsored by Bayer · Observational
The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients with acute deep vein thrombosis treated with Xarelto, in accordance with the terms of the European marketing authorization and the Belgian reimbursement criteria.
1,506 studies on the registry are indexed under Thrombosis; 238 are open to participants now.
This study's enrollment of 131 is below the median of 213 across 586 observational studies indexed under Thrombosis.
Browse Thrombosis studies →Bayer is the lead sponsor of 1,643 studies on the registry; 57 are open to participants now.
Of its 209 completed or terminated interventional studies of FDA-regulated products, 129 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Ambulatory or hospitalized patients coming from the vascular diseases clinic of the participating hospitals
Exclusion Criteria:
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Starting dose (3 weeks): 15 mg BID, then 15 mg OD or 20 mg OD.
Number of patients with major bleedings
Time frame: up to 1 year or 30 days after end of rivaroxaban
Number of patients with symptomatic recurrent Venous Thrombus Embolism (VTE)
Time frame: up to 1 year or 30 days after end of rivaroxaban
All-cause mortality
Time frame: up to 1 year or 30 days after end of rivaroxaban
Adverse events
Time frame: up to 1 year or 30 days after end of rivaroxaban
Treatment satisfaction measured by means of Anti-clot treatment scale (ACTS)
Time frame: up to 1 year or 30 days after end of rivaroxaban
Quantities of resource use consumption
Time frame: up to 1 year or 30 days after end of rivaroxaban
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bayer